VB is considered to have significant clinical value from a cancer perspective, owing to its neuroprotective and memory enhancement properties.26 In agreement with our data, Areeb et al illustrated that let‐7g‐5p was significantly poorly expressed in patients with GBM.27 The in silico target prediction and the luciferase activity assay demonstrated HMGA2 was a putative target gene of let‐7g‐5p, which was negatively governed by let‐7g‐5p. The gene discussed is HMGA2; the disease is glioblastoma.